Marion Leduc

Inserm, Institut Universitaire de France

Papers

2

Total Citations

80

H-Index

2

About

Marion Leduc is a leading researcher in autophagy and cancer biology, whose work bridges the gap between cellular degradation pathways and therapeutic innovation. Her primary research areas include autophagy modulation, high-throughput drug screening, and the intersection of cancer metabolism with immune-dependent mechanisms. Leduc’s most notable contribution is her 2021 study demonstrating that IGF1 receptor inhibition amplifies the effects of cancer drugs through both autophagy and immune-dependent mechanisms—a finding with 77 citations that has reshaped understanding of how targeted therapies can be synergized. This work emerged from a high-content, robotized screen of 65,000 compounds, showcasing her expertise in large-scale pharmacological discovery. In the same year, she also advanced methodological standards with her paper on high-throughput screening for autophagy, providing a foundational tool for the field. Leduc’s research holds translational promise for age-associated diseases and cancer, positioning her as a key figure in the quest to harness autophagy for therapeutic benefit. Her achievements reflect a rare combination of technical rigor and conceptual insight, making her work essential reading for students and researchers exploring autophagy-based interventions.

Research Focus

Key Achievements

2
H-Index
2
Papers
80
Total Citations
40
Avg Citations/Paper
🏆 Most Cited Paper
IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms
77 citations · 2021
📈 Most Prolific Year: 2021 (2 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: Inserm, Institut Universitaire de France

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago